SR-3306 is primarily utilized in research settings for its role as a selective inhibitor of c-Jun N-terminal kinase (JNK). This compound is particularly valuable in studying the pathways and mechanisms associated with JNK signaling, which is implicated in various cellular processes including apoptosis, inflammation, and stress responses. Researchers employ SR-3306 to investigate its potential therapeutic effects in diseases where JNK activity is dysregulated, such as neurodegenerative disorders, cardiovascular diseases, and certain types of cancer. By inhibiting JNK, SR-3306 helps in understanding the molecular basis of these conditions and in the development of targeted treatments. Additionally, it is used in preclinical studies to assess its efficacy and safety profile, providing insights into its potential as a drug candidate.